{"id":"dexamfetamine-sulphate","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamfetamine is the active d-isomer of amphetamine that enhances catecholaminergic neurotransmission by stimulating the release of dopamine and norepinephrine from presynaptic terminals and inhibiting their reuptake via monoamine transporters. This results in increased synaptic concentrations of these neurotransmitters, leading to enhanced alertness, focus, and motor activity. It is commonly used in the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.","oneSentence":"Dexamfetamine sulphate is a central nervous system stimulant that increases the release and blocks the reuptake of dopamine and norepinephrine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:17.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT05529927","phase":"PHASE2","title":"Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Parnassia Addiction Research Centre","startDate":"2026-05","conditions":"Cocaine Use Disorder","enrollment":204},{"nctId":"NCT06967857","phase":"PHASE2","title":"Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression","status":"RECRUITING","sponsor":"Prof. Dr. Frank Behrens","startDate":"2025-05-15","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder","enrollment":105},{"nctId":"NCT04946461","phase":"","title":"The Day-time Response Variation of (Lis)Dexamphetamine","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2021-07-01","conditions":"Adhd","enrollment":16},{"nctId":"NCT04968522","phase":"PHASE4","title":"FASST - Fetal Alcohol Spectrum Stimulant Trial","status":"UNKNOWN","sponsor":"Monash Medical Centre","startDate":"2022-02-14","conditions":"Fetal Alcohol Spectrum Disorders","enrollment":20},{"nctId":"NCT01615887","phase":"PHASE2","title":"Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2009-11","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT04647903","phase":"PHASE1","title":"Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)","status":"COMPLETED","sponsor":"Vallon Pharmaceuticals, Inc.","startDate":"2020-10-05","conditions":"ADHD, Narcolepsy","enrollment":55},{"nctId":"NCT00152035","phase":"PHASE3","title":"Safety of SPD465 in Treating Adults With ADHD.","status":"COMPLETED","sponsor":"Shire","startDate":"2005-03-10","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":505},{"nctId":"NCT02884544","phase":"PHASE2","title":"A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2016-08","conditions":"Attention-Deficit Hyperactivity Disorder (ADHD)","enrollment":22},{"nctId":"NCT00152022","phase":"PHASE3","title":"Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.","status":"COMPLETED","sponsor":"Shire","startDate":"2005-04-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":412},{"nctId":"NCT00150579","phase":"PHASE3","title":"Efficacy and Safety of SPD465 in Adults With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2005-01-27","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":240},{"nctId":"NCT00202605","phase":"PHASE2","title":"Safety and Efficacy of SPD465 in Adults With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2005-09-29","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":72},{"nctId":"NCT03327402","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2018-03-13","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":24},{"nctId":"NCT04232644","phase":"PHASE1","title":"Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)","status":"COMPLETED","sponsor":"Vallon Pharmaceuticals, Inc.","startDate":"2019-05-27","conditions":"ADHD, Narcolepsy","enrollment":16},{"nctId":"NCT02668926","phase":"PHASE1","title":"Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT03019822","phase":"EARLY_PHASE1","title":"Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-02-01","conditions":"Healthy","enrollment":28},{"nctId":"NCT03223844","phase":"NA","title":"Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2018-01-01","conditions":"Schizophrenia, Psychosis, Sensitisation","enrollment":22},{"nctId":"NCT00218348","phase":"PHASE2","title":"Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2003-09","conditions":"Cocaine-Related Disorders","enrollment":186},{"nctId":"NCT02363075","phase":"PHASE3","title":"Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-04","conditions":"Glioma","enrollment":58},{"nctId":"NCT02203786","phase":"PHASE2","title":"D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2009-09","conditions":"Pathological Gambling","enrollment":60},{"nctId":"NCT01886469","phase":"PHASE1, PHASE2","title":"A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2013-07","conditions":"Attention-Deficit Hyperactivity Disorder","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Magisterial Dexamfetamine","Tentin"],"phase":"phase_3","status":"active","brandName":"Dexamfetamine sulphate","genericName":"Dexamfetamine sulphate","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamfetamine sulphate is a central nervous system stimulant that increases the release and blocks the reuptake of dopamine and norepinephrine in the brain. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}